Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

CS-6253

Alternative Names: CS-6253, CS 6253, CS6253
Latest Update: 2025-05-11
Latest Update Note: Clinical Trial Update

Product Description

Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of prebeta-1 HDL In Vitro. (Sourced from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0131997)

Mechanisms of Action: ABCA1 Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Artery Therapeutics, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CS-6253

Countries in Clinic: Spain

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ATI-CS-001

P1

Completed

Alzheimer Disease

2024-07-31

50%

Recent News Events

Date

Type

Title

12/15/2023

PubMed

 A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.

06/24/2022

PubMed

 Effect of the ABCA1 agonist CS-6253 on amyloid-beta and lipoprotein metabolism in cynomolgus monkeys.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions